Abstract
Nowadays, the implementation of quality by design approach in analytical method development based on principles of quality risk management (QRM) and design of experiments (DoE) has became a regulatory requirement. Hence, a precise, accurate and robust high-performance thin-layer chromatography method has been developed for the simultaneous estimation of azilsartan medoxomil (AZM) and chlorthalidone (CLT) by the implementation of QRM- and DoE-based quality by design approach. QRM was performed by the identification of probable method risk parameters and their assessment by allotting a risk priority number. DoE was implemented by Placket-Burman screening design and Box-Behnken response surface analysis using Design-Expert software (trial version) by selecting resolution and tailing factor as critical method attributes. Method operable design region (MODR) was navigated for development of the method as per the analytical target profile (ATP). Chromatographic separation was performed using silica gel GF254 as the stationary phase and toluene‒methanol‒ethyl acetate‒formic acid (7:2:1:0.2, V/V) as the mobile phase in twin-trough chamber keeping a saturation time of 15 min. The developed method was validated as per the International Conference on Harmonization Q2 (R1) guideline. The developed method was applied for the assay of combined pharmaceutical dosage forms of AZM and CLT and the results were found in good agreement with their labelled claim.
Similar content being viewed by others
References
EDARBYCLOR (2019) (azilsartan medoxomil and chlorthalidone)—FDA. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202331lbl.pdf
Indian Pharmacopoeia (2018) Vol. 1, 2 and 3. The Indian Pharmacopoeia Commission, Ghaziabad, Govt. of India, Ministry of Health and Family Welfare, pp 847–848, 1076–1078.
British Pharmacopoeia (2018) Vol. 2. The Department of Health, Grat Britain: Medicines and Healthcare products Regulatory Agency (MHRA), pp 185–186, 484–485.
The United States Pharmacopeia-28 (2018) Asian edn., USP Convention, Rockville, MD, pp 1739–1740, 4753.
Sangshetti JN, Deshpande M, Zaheer Z, Shinde D, Arote R (2017) Quality by design approach: regulatory need. Arab J Chem 10(2):S3412–S3425
Dejaegher B, Heyden YV (2011) Experimental designs and their recent advances in set-up, data interpretation, and analytical applications. J Pharm Biomed Anal 56(2):141–158
Bhutani H, Kurmi M, Beg S, Singh B (2014) Quality by design (QbD) in analytical sciences: an overview. Pharma Times 46:71–75
Vogt FG, Kord AS (2011) Development of quality-by-design analytical methods. J Pharma Sci 100(3):797–812
Surwade KS, Saudagar RB (2015) UV Spectrophotometric method for the estimation of azilsartan medoxomil in bulk and pharmaceutical formulations. World J Pharma Res 4(1):1667–1672
Ingle SU, Patil PA, Kulkarni VC, Patil SV, Salunke PA, Wagh RS (2014) Development and validation of UV spectrophotometric method for chlorthalidone in bulk and pharmaceutical dosage forms. World J Pharma Res 3(9):958–963
Ebeid WM, Elkady EF, El-Zaher AA, Pantonay G (2014) Spectrophotometric and spectrofluorometric studies on azilsartan medoxomil and chlorthalidone to be utilized in their determination in pharmaceuticals. Anal Chem Insights 9:33–40. https://doi.org/10.4137/ACI.S13768
Masthanamma SK, Jahnavi P (2014) Stability Indicating RP-HPLC method for determination of azilsartan medoxomil in pharmaceutical dosage form. Res J Pharm Tech 7(2):168–172
Muthyala N, Naresh B (2019) Stability indicating RP-HPLC method development and validation for the quantitative estimation chlorthalidone in API and tablet dosage form. Int J Adv Res Med Pharma Sci 4(10):32–41
Sohni SK, Kumar R, Akhtar M, Ranjan C, Chavala G (2016) Development and validation of RP-HPLC method for simultaneous estimation of azilsartan medoximil and chlorthalidone in bulk form and formulation using quality by design. Int J Pharm Sci 8(2):266–272
Naazneen S, Sridevi A (2014) Stability-indicating RP-HPLC method for the simultaneous estimation of azilsartan medoxomil and chlorthalidone in solid dosage forms. Inter J Pharm Pharm Sci 6(6):226
Peraman R, Dakinedi S, Kadiri RR, Malineni L (2017) Reliable and sensitive stability indicating—liquid chromatographic method for determination of azilsartan medoxomil and characterization of common hydrolytic degradation product. J Young Pharm 9(2):197–202
Ebeid WM, Walid MA, Enab E, Asma AE (2014) Stability-indicating RP-LC method for determination of azilsartan medoxomil and chlorthalidone in pharmaceutical dosage forms: application to degradation kinetics. Anal Bioanal Chem 406(26):6701–6712. https://doi.org/10.1007/s00216-014-8085-0
NalawadeV JS (2019) Development and validation of LC-MS/MS method for simultaneous determination of azilsartan medoxomil and chlorthalidone from the human plasma. J Pharm Sci Res 11(7):2533–2537
Acknowledgements
The authors would like to thank Glenmark Pharmaceuticals, Nashik, India, for providing the gift sample of azilsartan medoxomil and chlorthalidone. The authors would also like to thank the principal, Maliba Pharmacy College, for providing all the required infrastructure and facilities needed to complete this research work.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Prajapati, P., Patel, S. & Mishra, A. Simultaneous estimation of azilsartan medoxomil and chlorthalidone by chromatography method using design of experiment and quality risk management based quality by design approach. JPC-J Planar Chromat 33, 631–646 (2020). https://doi.org/10.1007/s00764-020-00067-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00764-020-00067-4